

## Info Sheet for Technical description

No. 0018

### Organization

\* Mandatoty fields

Name of Organization*	Myoridge Co. Ltd.	
Address, City, States, Zip, Country*	14 Yoshidakawara-cho, Sakyo-ku, Kyoto, 606-8305, Japan	
URL	<a href="https://myoridge.co.jp/en/">https://myoridge.co.jp/en/</a>	
Brief Descriptions of Organization* (Approx. 100 words)	Myoridge is a commercial stage startup that spun out of Kyoto university in Japan. We mainly offer culture media optimization for cell therapy products, and cultured foods. Our core competency is creating optimized culture media according to customer needs leveraging our deep scientific expertise and proprietary platform. For example, we successfully reduced cost of culture media for iPS cell-derived cardiomyocytes by >90%.	
Contact address	Name*	Takeo Suzuki
	Department* / Position	Board Director/Head of Business Division, CMO
	E-mail* / TEL	suzuki@myoridge.co.jp/070-1465-7892

### What kind of technology do you want to offer? \*

- A.** Clinical Development Pipelines → Please see **Sheet [A]**
- B.** Regenerative Medicine-related Consumables / Instruments / Materials / CDMO Services etc. → Please see **Sheet [B]**
- C.** Platform Technologies(\*) that are not included in the above (Group B) → Please see **Sheet [C]**
- \* Peripheral technologies that contribute to a significant improvement in productivity throughout the value chain of pharmaceuticals, from research and development to manufacturing and ultimately market launch.

### If you agree to the following, please check "Yes" below. \*

The technologies introduced in this 'Info Sheet' are in the public domain, as they have been published in research papers or have related patent applications.

- Yes

### Do you have any collaborations/partnerships with pharmaceutical companies?

- Yes
- No

### If you have already received funding from VCs or other sources, up to which stage has the investment round progressed?

- Angel / Seed (including AMED/JST grants)
- Series A
- Series B
- Series C
- Series D or further advanced stages

### Do you agree to leave your presentation materials at FIRM hands and entrust us to make use of them for the purpose of promoting your partnering opportunities? \*

Options*	Comments
<input checked="" type="checkbox"/> Yes	
<input type="checkbox"/> No	

Filled in by\*

Date\*

Takeo Suzuki
3-Sep-24

<b>Info Sheet for Technical overview</b>
--

No.0018

\* Mandatoty fields

**Title\***

<b>Culture media optimization</b>
-----------------------------------

**Category\***

- |   |  |   |
|---|--|---|
| <input type="checkbox"/> Facilities                                   | <input type="checkbox"/> Manufacturing equipment   | <input type="checkbox"/> Inspection equipment |
| <input type="checkbox"/> Cells  | <input checked="" type="checkbox"/> Culture medium | <input type="checkbox"/> Reagents             |
| <input type="checkbox"/> Cell banking                                 | <input type="checkbox"/> Storage / Container       | <input type="checkbox"/> Logistics            |
| <input type="checkbox"/> Cell / Viral vector manufacturing technology |  |   |

**Description\***

We propose culture medium optimization service using our unique medium components library for issues in cell culture such as cell phenotype, reproducibility of cell culture, safety and cost of medium.

Benefits of Myoridge's medium development service

- Utilizing our unique culture medium component library, we propose custom culture media in response to user issues.
- Based on our original serum-free medium, we can develop a medium that excludes specific components such as animal-derived components and expensive growth factors.
- Achieve medium optimization in a short period of time (minimum 2 to 3 months) with high-throughput screening.
- Disclosure of medium composition is also available as an option.

**Filled in by\***

Takeo Suzuki

**Date\***

3-Sep-24